Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
Trade NameORAQUICK HCV RAPID ANTIBODY TEST
Classification Nameassay,enzyme linked immunosorbent,hepatitis c virus
ApplicantORASURE TECHNOLOGIES INC.
PMA NumberP080027
Date Received10/24/2008
Decision Date06/25/2010
Product Code
MZO[ Registered Establishments with MZO ]
Docket Number 10M-0402
Notice Date 07/30/2010
Advisory Committee Microbiology
Expedited Review Granted? No
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the oraquick rapid hcv antibody test. The device is indicated for the qualitative detection of antibodies to hepatitis c virus (anti-hcv) in venipuncture whole blood specimens (edta, sodium heparin, lithium heparin, and sodium citrate) from individuals 15 years or older. The oraquick hcv rapid antibody test results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hcv (state of infection or associated disease not determined) in persons with signs or symptoms of hepatitis and in persons at risk for hepatitis c infection.
Approval Order Approval Order
Supplements: S001 S003 S005 S006 S007 S008 
S009 S010 
-
-